Dapagliflozin (Farxiga) structure · SGLT2 inhibitor

Dapagliflozin (Farxiga) 2D structure

Role: Drug
Family: SGLT2 inhibitor series
Mechanism class: SGLT2 inhibitor
Parent scaffold: C-glucoside SGLT2 pharmacophore
Indication: T2D, HF, CKD · FDA/EMA

Structure source: Catalog seed (external identifier on file)
PubChem CID: 9887712
ChEMBL ID: CHEMBL184270
FDA / EMA: FDA/EMA
ClinicalTrials.gov: dapagliflozin CKD
Regulatory status: Approved · FDA/EMA · ClinicalTrials.gov · ClinicalTrials.gov

How similarity is calculated

Hand-written analysis

Mechanism

다파글리플로진도 SGLT2 저해로 당뇨·심부전·CKD에 쓰입니다. 기전은 엠파글리플로진과 동일 층입니다. 체액량·감염 모니터링이 같습니다.

Medicinal chemistry

C-글루코사이드에 클로로벤질 치환이 있습니다. 소타글리플로진은 SGLT1/2 이중으로 갈립니다.

Indication · context

대사·심신 적응이 겹칩니다. SGLT2 허브에서 구조 차이를 봅니다.

SMILES

CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)C5=CC=CC=C5)OCC6C(C(C(C(O6)CO)O)O)O

Related compounds

Comparisons · briefs

External IDs · BioMoa

PubChem CID 9887712 CHEMBL184270 BioMoa · SGLT2 / Farxiga BioMoa bridge Open on the family map Flow Structure table Mechanism class

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Methodology

Dapagliflozin (Farxiga) structure · mechanism